A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

NCT06984627 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Graves' Disease

Interventions

DRUG: Rilzabrutinib dose 1
DRUG: Rilzabrutinib dose 2

Sponsor

Sanofi